EMBAR

Author:
Kunwar Abdul Kalam , Dr. Suneel Kumar Niranjan
Research Scholar , Institute of Pharmacy, Bundelkhand University, Jhansi

Published Date: 21-Jul, 2023

Keywords: Propranolol hydrochloride, Sustained-release tablets, Formulation development, Drug release profile, Patient compliance

Abstract:
The purpose of this research is to develop and test extended-release tablets of propranolol hydrochloride, a non-selective beta-adrenergic antagonist used in the treatment of cardiovascular conditions. The advance of a sustained-release formulation aims to address the limitations of immediate-release dosage forms, including the need for frequent administration and potential fluctuations in drug concentrations.The materials and methods section describes the selection of appropriate excipients, such as hydrophilic polymers, release modifiers, diluents, lubricants, and other additives, to achieve sustained drug release. The dry granulation method was employed to create the sustained-release tablets.The tablet composition for different formulations was provided, highlighting the varying amounts of propranolol hydrochloride and excipients used in each formulation. Comparative analysis of tablet core and film coating was conducted, including assessments of general appearance, weight variation, thickness, hardness, and friability. These tests ensure the quality and physical characteristics of the tablets.In vitro drug release studies demonstrated controlled and sustained release of propranolol over the desired period, indicating that the sustained-release tablets can maintain therapeutic drug levels within the desired range. This sustained release profile offers several advantages, reduced side effects, including improved patient compliance, and enhanced therapeutic efficacy.Stability studies were conducted on a selected formulation to assess its long-term stability and shelf life under accelerated storage conditions. The formulation was subjected to physical character assays and in vitro dissolution tests after 1, 2, and 3 months. The results of these studies provide insights into the stability and performance of the sustained-release tablets over time.Overall, this research presents a comprehensive approach to formulating and evaluating sustained-release tablets of propranolol hydrochloride. The findings support the potential of these tablets to provide a convenient and effective treatment option for cardiovascular conditions, offering prolonged drug release, improved patient compliance, and optimized therapeutic outcomes.

References: